Regeneron profit beats estimates on strong sales of key drugs

(Reuters) - U.S. drugmaker Regeneron Pharmaceuticals Inc's quarterly profit and revenue beat estimates, helped by strong demand for its new eczema drug Dupixent and its flagship eye treatment Eylea.